Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph plus ) leukemias resistant or intolerant to imatinib

被引：1
|
作者：
Rosenberg, J. A.
Derreumaux, D.
Gore, L.
Kearns, P.
Baruchel, A.
Barrett, T.
Zwaan, M.
机构：
[1] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[2] Bristol Myers Squibb Co, Braine Lalleud, Belgium
[3] Univ Colorado Denver, Aurora, CO USA
[4] Childrens Hosp, Aurora, CO USA
[5] Univ Birmingham, Birmingham, W Midlands, England
[6] Hop St Louis, Paris, France
[7] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Rotterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps281
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS281
引用
收藏
页数：1
相关论文
共 50 条
  • [21] SIX-YEAR FOLLOW-UP OF PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING DASATINIB
    Rea, D.
    Vellenga, E.
    Junghanss, C.
    Baccarani, M.
    Kantarjian, H.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 80 - 80
  • [22] DASATINIB LACK OF CROSS INTOLERANCE TO IMATINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (CML-CP) WHO ARE INTOLERANT TO IMATINIB - A RETROSPECTIVE SAFETY ANALYSIS
    Guilhot, E.
    Goldberg, S. L.
    Stone, R. M.
    Mauro, M.
    Matloub, Y.
    Chen, T. T.
    Khoury, H. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 51 - 51
  • [23] Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety
    Khoury, H. J.
    Goldberg, S. L.
    Mauro, M. J.
    Stone, R. M.
    Matloub, Y.
    Chen, T.
    Guilhot, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] EFFICACY OF NILOTINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED, PREVIOUSLY UNTREATED PHILADELPHIA CHROMOSOME (PH)-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN EARLY CHRONIC PHASE (CML-CP)
    Cortes, J.
    Jones, D.
    O'Brien, S.
    Ferrajoli, A.
    Borhtakur, G.
    Burger, J.
    Wierda, W.
    Garcia-Manero, G.
    Letvak, L.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 48 - 48
  • [25] DASATINIB COMPARED TO IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC-PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP): RESULTS FROM THE RANDOMIZED PHASE 3 DASISION TRIA
    Baccarani, M.
    Shah, N.
    Kantarjian, H.
    Cortes, J.
    Shah, S.
    Ayala, M.
    Moiraghi, B.
    Mayer, J.
    Bradley-Garelik, M.
    Zhu, C.
    Hochhaus, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 231 - 231
  • [26] Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Jones, Dan
    Jabbour, Elias
    Konopleva, Marina
    Ferrajoli, Alessandra
    Kadia, Tapan
    Borthakur, Gautam
    Stigliano, Denise
    Shan, Jenny
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 144 - 145
  • [27] Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'
    Rosti, Gianantonio
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Palandri, Francesca
    Martinelli, Giovanni
    Baccarani, Michele
    LEUKEMIA & LYMPHOMA, 2010, 51 (04) : 583 - 591
  • [28] Phase II study of 5-aza-2′-deoxycytidine (decitabine) in patients (pts) with Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML) resistant or intolerant to imatinib mesylate.
    Issa, JP
    Garcia-Manero, G
    Talpaz, M
    Cortes, J
    Giles, F
    Vestovsek, S
    Faderl, S
    O'Brien, S
    Morris, G
    Kantarjian, H
    BLOOD, 2003, 102 (11) : 910A - 910A
  • [29] Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph plus CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data
    Li, Nanxin
    Yang, Chelsey
    Fan, Liangyi
    Totev, Todor
    Guerin, Annie
    Chen, Lei
    BLOOD, 2015, 126 (23)
  • [30] Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP)
    Jabbour, E.
    le Coutre, P.
    Baccarani, M.
    Bhalla, K.
    Ossenkoppele, G. J.
    Hochhaus, A.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345